Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Open Orphan Plc ( (GB:HVO) ) has issued an announcement.
hVIVO plc announced it will release its interim results for the first half of 2025 on 23 September 2025. The company will hold a briefing for equity research analysts and a live investor presentation on the same day, allowing stakeholders to engage with the company’s leadership. This announcement underscores hVIVO’s commitment to transparency and engagement with its investors, potentially impacting its market position positively.
The most recent analyst rating on (GB:HVO) stock is a Buy with a £11.50 price target. To see the full list of analyst forecasts on Open Orphan Plc stock, see the GB:HVO Stock Forecast page.
Spark’s Take on GB:HVO Stock
According to Spark, TipRanks’ AI Analyst, GB:HVO is a Outperform.
The overall stock score reflects strong valuation and financial performance, with a low P/E ratio and robust revenue growth. However, technical analysis indicates bearish trends, which slightly offset the positive valuation and financial metrics. The absence of earnings call data means corporate events were not factored into the score, although they present a positive outlook.
To see Spark’s full report on GB:HVO stock, click here.
More about Open Orphan Plc
hVIVO plc is a full-service Contract Research Organisation (CRO) and the global leader in human challenge trials. The company provides end-to-end clinical development services to a diverse client base, including major biopharma companies. Specializing in human challenge trials across infectious and respiratory indications, hVIVO operates a state-of-the-art quarantine facility in London and offers virology and immunology laboratory services under the hLAB brand. Through its subsidiaries, CRS and Venn Life Sciences, hVIVO offers early-phase clinical trial services and drug development consulting, supporting a seamless pathway from preclinical stages to late-stage development.
Average Trading Volume: 2,026,838
Technical Sentiment Signal: Sell
Current Market Cap: £68.01M
See more data about HVO stock on TipRanks’ Stock Analysis page.